MAPT and Alzheimer disease: Aβ and tau pathology can be detected by cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) imaging in the preclinical stage of AD, decades prior to the cognitive impairment seen in mild cognitive impairment (MCI) or dementia (Dubois et al., 2016).